Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22983046 | 1.00 | ACACA (0.34) | ACACAACACB | |
| SCHEMBL22994432 | 0.86 | ACACA (0.39) | ACACAACACB | |
| SCHEMBL22994564 | 0.86 | ACACA (0.39) | ACACAACACB | |
| SCHEMBL24692524 | 0.77 | ACACA (0.36) | ACACAACACB | |
| SCHEMBL5129886 | 0.77 | PDE4A (0.35) | ACACAACACB | |
| SCHEMBL18907912 | 0.75 | ALDH1A1 (0.33) | — | |
| SCHEMBL18907349 | 0.75 | ALDH1A1 (0.33) | — | |
| SCHEMBL22994560 | 0.73 | ACACA (0.40) | ACACAACACB | |
| SCHEMBL22994461 | 0.72 | ACACB (0.41) | ACACAACACB | |
| SCHEMBL18959801 | 0.72 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4010344-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11352371-B2 | Thienopyrimidine derivatives as ACC inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210053990-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2021030142-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352371-B2 | Thienopyrimidine derivatives as ACC inhibitors and uses thereof | ACACB, ACACA, ACAT2 | ACACA 2/4885ACACB 1/4885 |
| US-20210053990-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACA 1/4885ACACB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.